Prescient Investment Analysis
Value, growth at reasonable price, long/short equity, bankruptcy situations

A Close Look At ArQule

ArQule, Inc. (NASDAQ:ARQL) is an oncology-focused microcap biotechnology company. A graphical description of its pipeline shows six ongoing clinical trials studying five products. Its shares currently trade for under $2.20, after moving up and then down again in 2014, pursuant to depreciating through the past year and being removed from the NASDAQ Biotechnology Index (NASDAQ:IBB) on December 23rd.

ArQule has some cash on hand as well as investments. Though the company has obtained funds through partnerships, and might continue to in the future, it is not financially self-sustaining. Yet, there appear to be multiple ways for the experimental firm to reward investors. One reason is that it has a considerable amount of Net Operating Losses ("NOL")...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details